Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

9
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
9
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.6K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.7K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.7K
Autoimmune Disorders01:29

Autoimmune Disorders

2.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropathic pain in multiple sclerosis: discrepancies between DN4 screening and neurophysiological measures.

Multiple sclerosis and related disorders·2026
Same author

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Complications, outcomes, and implications of a prolonged vegetative state in anti-NMDA receptor encephalitis: a retrospective international cohort study.

The Lancet. Neurology·2026
Same author

Soluble c-Met correlates with NfL and GFAP levels in the CSF of patients with multiple sclerosis.

Journal of neuroimmunology·2026
Same author

Risk of false-positive findings in the assessment of small nerve fibers in healthy subjects.

Journal of neurology·2026
Same author

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Clinical chemistry and laboratory medicine·2025
Same journal

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

Swiss medical weekly·2026
Same journal

Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery.

Swiss medical weekly·2026
Same journal

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study.

Swiss medical weekly·2026
Same journal

Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022.

Swiss medical weekly·2026
Same journal

Microplastics in the air and potential health risks - a narrative review.

Swiss medical weekly·2026
Same journal

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

15.9K

Update on multiple sclerosis treatments.

Claire Bridel1, Patrice H Lalive2

  • 1Department of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis, Geneva University Hospital and Faculty of Medicine of the University of Geneva, Switzerland.

Swiss Medical Weekly
|September 24, 2014
PubMed
Summary
This summary is machine-generated.

Managing relapsing-remitting multiple sclerosis (RRMS) is complex due to new therapies. This review details current and upcoming disease-modifying therapies, covering efficacy, side effects, and patient management for RRMS.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K

Related Experiment Videos

Last Updated: Apr 23, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

15.9K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • The landscape of relapsing-remitting multiple sclerosis (RRMS) management has evolved significantly.
  • Numerous novel disease-modifying therapies (DMTs) are now available, enabling personalized treatment strategies.

Purpose of the Study:

  • To provide a comprehensive overview of currently available and emerging DMTs for RRMS.
  • To summarize critical information regarding treatment efficacy, safety, and patient management.

Main Methods:

  • Literature review of available clinical trial data and post-marketing surveillance.
  • Synthesis of information on efficacy, adverse events, monitoring guidelines, vaccination protocols, and pregnancy considerations for DMTs.

Main Results:

  • Detailed efficacy and safety profiles for a wide range of DMTs.
  • Specific recommendations for patient follow-up, including monitoring for side effects and managing comorbidities.
  • Guidance on vaccinations and reproductive health in the context of RRMS treatment.

Conclusions:

  • The increasing number of DMTs offers tailored options for RRMS but complicates patient follow-up.
  • A thorough understanding of each therapy's profile is essential for optimizing individualized patient care and outcomes in RRMS.